ライフサイエンスコーパス: thyroid cancer

1 se that undergoes rearrangement in papillary thyroid cancer).

2 increased rate of thyroidectomy for treating thyroid cancer.

3 ition to VEGFR and is approved for medullary thyroid cancer.

4 mortality rate for advanced-stage papillary thyroid cancer.

5 e PTEN oxidation and nuclear accumulation in thyroid cancer.

6 extrapolated from staging for differentiated thyroid cancer.

7 es for future studies of the pathogenesis of thyroid cancer.

8 al extent of thyroidectomy for patients with thyroid cancer.

9 lin (TG), a protein marker of differentiated thyroid cancer.

10 breast cancer in premenopausal women or for thyroid cancer.

11 patients with BRAF(V600E)-positive papillary thyroid cancer.

12 in vivo in murine xenograft models of human thyroid cancer.

13 ertain types of cancers such as melanoma and thyroid cancer.

14 ts and harms of treatment of screen-detected thyroid cancer.

15 radioactive iodine-refractory differentiated thyroid cancer.

16 d tailored management of thyroid nodules and thyroid cancer.

17 sed at highest levels in PDTC and anaplastic thyroid cancer.

18 oid cells and in mice with BrafV600E-induced thyroid cancer.

19 ng strategy for the treatment of BRAF-mutant thyroid cancer.

20 s that may be associated with differentiated thyroid cancer.

21 es, driven largely by increases in papillary thyroid cancer.

22 mmunoPET approach for noninvasive imaging of thyroid cancer.

23 te among patients with iodine-131-refractory thyroid cancer.

24 of ATF4 during the pathogenesis of medullary thyroid cancer.

25 for the associations of obesity and BSA with thyroid cancer.

26 ound between body mass index and the risk of thyroid cancer.

27 roid cancer and in 4.7% of 423 patients with thyroid cancer.

28 stalk between SDHD and PTEN in CS-associated thyroid cancer.

29 de uptake for improved treatment of advanced thyroid cancer.

30 an association between exposure to PBDEs and thyroid cancer.

31 role of BSA and excess weight in the risk of thyroid cancer.

32 h the risk allele of rs965513 predisposes to thyroid cancer.

33 gy-associated pathogenesis of differentiated thyroid cancer.

34 SF3 may be involved in the predisposition of thyroid cancer.

35 creased access to the surgical management of thyroid cancer.

36 ase-free survival in patients with papillary thyroid cancer.

37 %) died from incidentally detected medullary thyroid cancer.

38 rce (USPSTF) recommendation on screening for thyroid cancer.

39 sortilin as potential therapeutic targets in thyroid cancer.

40 ct of insurance statuses on the treatment of thyroid cancer.

41 1.1%-4.7%) for SEER distant stage papillary thyroid cancer.

42 ng (including overdiagnosis) or treatment of thyroid cancer.

43 mmune system in the pathogenesis of advanced thyroid cancers.

44 vering new adjuvant therapies for aggressive thyroid cancers.

45 eriments with thyrocytes from the PPFP mouse thyroid cancers.

46 oducing C-cells and accounts for 3-5% of all thyroid cancers.

47 re malignancy that accounts for 1%-2% of all thyroid cancers.

48 ificantly more CSCs than well-differentiated thyroid cancers.

49 s of human RAS-driven, poorly differentiated thyroid cancers.

50 ours, and a subset of malignant melanoma and thyroid cancers.

51 inical behavior and outcome of patients with thyroid cancers.

52 mmon subsequent malignancies were breast and thyroid cancers.

53 thologic evaluation, 47 (36%) had incidental thyroid cancer (24 papillary, 11 malignant FNA, 5 oncocy

54 or rearrangements that are commonly found in thyroid cancer (7-gene panel).

55 cer activity than the allele associated with thyroid cancer (A).

56 oid nodules, diffuse (18)F-FDG uptake, known thyroid cancer, abnormalities adjacent to the thyroid, a

57 Familial nonmedullary thyroid cancer accounts for 3 to 9% of all cases of thyr

58 cancer (aIRR, 2.46; 95% CI, 1.03-5.91), and thyroid cancer (aIRR, 3.37; 95% CI, 1.55-7.33).

59 p and cleft palate (CLP), hypothyroidism and thyroid cancer all map to the FOXE1 locus, but causative

60 ents undergoing total thyroidectomy, 47% had thyroid cancer and 53% benign disease.

61 ents undergoing total thyroidectomy, 47% had thyroid cancer and 53% benign disease.

62 The diagnosis of thyroid cancer and diffuse parenchymal disorders is gene

63 and associated with advanced differentiated thyroid cancer and higher mortality rate.

64 was associated with advanced differentiated thyroid cancer and higher mortality.

65 pecific recommendations exist for follicular thyroid cancer and Hurthle cell carcinoma in evidence-ba

66 bers of a kindred with familial nonmedullary thyroid cancer and in 4.7% of 423 patients with thyroid

67 yroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatme

68 unrelated mutation-negative CS probands with thyroid cancer and in The Cancer Genome Atlas (TCGA), re

69 ylation and reduced DR5 levels in both human thyroid cancer and melanoma cells.

70 for targeting the sodium-iodine symporter in thyroid cancer and nonthyroidal neoplasms as well as a b

71 egulated in ATC compared with differentiated thyroid cancer and normal tissue.

72 us on radioiodine therapy for differentiated thyroid cancer and peptide receptor radionuclide therapy

73 s of persons treated for well-differentiated thyroid cancer and persons with no surgery or surveillan

74 t advances in the diagnosis and treatment of thyroid cancer and provide the molecular basis for studi

75 e the association between (131)I therapy for thyroid cancer and risk of receiving cataract surgery in

76 surance who were admitted to a hospital with thyroid cancer and underwent a thyroidectomy between 200

77 in a patient who had radioiodine-refractory thyroid cancer and who underwent a redifferentiation tre

78 and inflammation in papillary and follicular thyroid cancers and the presence of multipotent mesenchy

79 inib (FDA-approved for progressive medullary thyroid cancer) and PF-04217903 block their activity at

80 in-embedded tissue slides from patients with thyroid cancer, and detect thousands of tumour-specific

81 d pathologists in the treatment of papillary thyroid cancer, and especially intermediate-risk disease

82 , test accuracy to detect thyroid nodules or thyroid cancer, and harms resulting from screening (incl

83 breast cancer, colorectal cancer, leukaemia, thyroid cancer, and non-Hodgkin lymphomas are the most c

84 at results in the identification of indolent thyroid cancers, and treatment of these overdiagnosed ca

85 primarily related to increases in papillary thyroid cancer (annual percent change, 4.4% [95% CI, 4.0

86 mor microenvironment (TME) to progression in thyroid cancer are largely unexplored and may illuminate

87 The majority of thyroid cancers are differentiated cancers with excellen

88 The great majority of thyroid cancers are of the non-medullary type.

89 Medullary thyroid cancer arises from calcitonin-producing C-cells

90 and human granulocytes (CD56-) or anaplastic thyroid cancer (ARO) cells in the contralateral thigh as

91 risk in patients after surgery for papillary thyroid cancer as a function of primary tumor stage and

92 thropometric risk factors for differentiated thyroid cancer at the time of diagnosis and at age 20 ye

93 ntiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are rare and frequently lethal tumo

94 Anaplastic thyroid cancer (ATC) is a rare malignancy that accounts

95 Anaplastic thyroid cancer (ATC) is one of the most lethal human mal

96 Anaplastic thyroid cancer (ATC), one of the most aggressive solid t

97 characteristic cell morphology of anaplastic thyroid cancer (ATC).

98 ded 761 adults diagnosed with differentiated thyroid cancer before 35 years of age between 2002 and 2

99 ity radioiodine therapies for differentiated thyroid cancer, blood dosimetry has been developed to es

100 ke do not affect risk for Graves' disease or thyroid cancer, but correction of iodine deficiency migh

101 cancer accounts for 3 to 9% of all cases of thyroid cancer, but the susceptibility genes are not kno

102 The incidence of detected thyroid cancer cases has been increasing in the United S

103 nctional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against

104 extracellular superoxide dismutase (SOD3) in thyroid cancer cell lines although according to recent d

105 eptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels

106 e in RAI-refractory papillary and follicular thyroid cancer cell lines.

107 RK signaling, which is markedly increased in thyroid cancer cells driven by oncogenic BRAF, represses

108 essential for proliferation and survival of thyroid cancer cells harboring PI3K-activating mutations

109 e, resulting in trans-differentiation of the thyroid cancer cells into adipocyte-like cells that lose

110 p27 expression and potentiated apoptosis in thyroid cancer cells while not affecting survival in nor

111 In thyroid cancer cells, oncogene activation prevented TGF-

112 he invasion, migration, and proliferation of thyroid cancer cells.

113 e tyrosine kinase (SRC) activity in invasive thyroid cancer cells; so, we explore bosutinib, a specif

114 th pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer

115 er a 2-fold increased prevalence (OR 2.7) of thyroid cancer compared to PTEN-associated CS but 50% de

116 CS but 50% decreased prevalence (OR 0.54) of thyroid cancer compared to SDHx-associated CS.

117 cts of sorafenib when used in differentiated thyroid cancer compared with renal and hepatocellular ca

118 Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P

119 p75(NTR) was overexpressed in anaplastic thyroid cancers compared with papillary and follicular s

120 TrkA was detected in 20% of thyroid cancers, compared with none of the benign sample

121 We note that the TCGA thyroid cancer dataset is enriched with unique germline

122 of sorafenib in patients with differentiated thyroid cancer demonstrated significantly higher rates o

123 Thyroid cancer demonstrates a broad variability of (18)F

124 Knockdown of RET by shRNA in medullary thyroid cancer-derived cells stimulated expression of ac

125 wed by its more common counterpart-papillary thyroid cancer-despite its unique biological behaviour a

126 The incidence of thyroid cancer detection has increased by 4.5% per year

127 The thyroid cancer detection rate increased from 24.6% to 41

128 pulation-based cohort study of patients with thyroid cancer diagnosed during the period 1998-2008.

129 cule offers a candidate biomarker to improve thyroid cancer diagnosis.

130 (131)I treatment for thyroid cancer did not increase the risk of receiving ca

131 ) in patients with metastatic differentiated thyroid cancer (DTC) and poorly differentiated thyroid c

132 Differentiated thyroid cancer (DTC) incidence has been reported to have

133 Patients with metastatic differentiated thyroid cancer (DTC) may be prepared using either thyroi

134 s of radioiodine treatment in differentiated thyroid cancer (DTC) patients.

135 everal susceptibility loci of differentiated thyroid cancer (DTC) were identified by previous genome-

136 er cohort of patients who had differentiated thyroid cancer (DTC) with that of a matched general popu

137 radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

138 etection of new nodules and the diagnosis of thyroid cancer during follow-up.

139 n p27 reorganizes the effects of TGF-beta in thyroid cancer, explaining the slow proliferation but la

140 Radioiodide (RAI) therapy of thyroid cancer exploits the relatively selective ability

141 E congeners were not associated with risk of thyroid cancer (for the fourth vs. first quartile of sum

142 16] years; 58213 [75%] women) diagnosed with thyroid cancer from 1974-2013, papillary thyroid cancer

143 patients in the United States diagnosed with thyroid cancer from 1974-2013, the overall incidence of

144 Somatic mutations in established thyroid cancer genes were detected in 14 of 22 (64%) tum

145 rmal animals and murine models of anaplastic thyroid cancer, glioblastoma, and triple-negative breast

146 Our study showed that anaplastic thyroid cancers had significantly more CSCs than well-di

147 ed by cancer type: colorectal, prostate, and thyroid cancers had the highest hazard ratios.

148 hether the increasing incidence of papillary thyroid cancer has been related to thyroid cancer mortal

149 The incidence of thyroid cancer has risen over the past decade, along wit

150 Most cases of thyroid cancer have a good prognosis; the 5-year surviva

151 About half of patients with papillary thyroid cancer have tumours with activating BRAF(V600E)

152 re approved for differentiated and medullary thyroid cancers have prolonged progression-free survival

153 r during function intervals), and kidney and thyroid cancers (higher during nonfunction intervals).

154 cer is the second most common differentiated thyroid cancer histological type and has been overshadow

155 O1 expression is significantly higher in all thyroid cancer histotypes compared with normal thyroid a

156 yroid nodules (HR, 6.3; 95% CI, 5.2 to 7.5), thyroid cancer (HR, 9.2; 95% CI, 6.2 to 13.7), growth ho

157 dney cancer: HR, 0.8; 95% CI, 0.7 to 0.8 and thyroid cancer: HR, 0.7; 95% CI, 0.6 to 0.8).

158 patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.

159 onse assessment of malignancy and represents thyroid cancer in approximately 35% of cases.

160 roid cancer screening and treatment of early thyroid cancer in asymptomatic adults to inform the US P

161 e on the benefits and harms of screening for thyroid cancer in asymptomatic adults, the diagnostic ac

162 The USPSTF recommends against screening for thyroid cancer in asymptomatic adults.

163 everal studies reported an increased risk of thyroid cancer in children and adolescents exposed to ra

164 idism, hyperthyroidism, thyroid nodules, and thyroid cancer in children and adolescents.

165 gs could explain the increased prevalence of thyroid cancer in CS patients with SDHx germline mutatio

166 per insight into the genetic contribution to thyroid cancer in different populations.

167 insurance had lower thyroidectomy rates for thyroid cancer in Massachusetts and the control states c

168 In 2013, the incidence rate of thyroid cancer in the United States was 15.3 cases per 1

169 nt with a true increase in the occurrence of thyroid cancer in the United States.

170 tions show some of the highest incidences of thyroid cancer in the world, and iodine deficiency is su

171 d specific immunoPET imaging was obtained of thyroid cancer in vivo in murine xenograft models of hum

172 Trends in thyroid cancer incidence and incidence-based mortality r

173 Annual percent changes in age-adjusted thyroid cancer incidence and incidence-based mortality r

174 To compare trends in thyroid cancer incidence and mortality by tumor characte

175 Thyroid cancer incidence has increased substantially in

176 Papillary thyroid cancer incidence increased for all SEER stages a

177 Thyroid cancer incidence increased, on average, 3.6% per

178 To our knowledge, thyroid cancer incidence is increasing faster than any o

179 Thyroid cancer incidence is increasing, and when fine-ne

180 nome-wide association study of non-medullary thyroid cancer, including in total 3,001 patients and 28

181 cer from 1974-2013, the overall incidence of thyroid cancer increased 3% annually, with increases in

182 In general, the risk of numerous thyroid cancers inevitably increases among people with i

183 neoplasia and present the resulting model of thyroid cancer initiation and progression.

184 Thyroid cancer is a major component cancer of Cowden syn

185 Anaplastic thyroid cancer is an aggressive and highly lethal cancer

186 Thyroid cancer is common, yet the sequence of alteration

187 presence of differentiated thyroid cells in thyroid cancer is critical for the antitumor response to

188 The incidence of differentiated thyroid cancer is increasing greatly in high-income coun

189 rmined that the net benefit of screening for thyroid cancer is negative.

190 ermissible activity (MPA) of (131)I to treat thyroid cancer is that which limits the absorbed dose to

191 Thyroid cancer is the fifth most common cancer in women

192 Thyroid cancer is the most common cancer in Korea.

193 Differentiated thyroid cancer is the most frequent subtype of thyroid c

194 Follicular thyroid cancer is the second most common differentiated

195 but their clinicopathologic significance in thyroid cancer is unclear.

196 one homeostasis, but their relationship with thyroid cancer is unknown.

197 y thyroid carcinoma (PTC), the most frequent thyroid cancer, is characterized by low proliferation bu

198 ogy from fine-needle aspiration can identify thyroid cancers, it is unclear if population-based or ta

199 is only when wild-type PTEN is expressed, in thyroid cancer lines.

200 of an antitumour immune response in advanced thyroid cancers linked to cytotoxic T cells and NK cells

201 pulation and the relatively low incidence of thyroid cancer make the preoperative identification of m

202 Patients with other, more rare subtypes of thyroid cancer-medullary and anaplastic-are ideally trea

203 Thyroid cancer morbidity and mortality, test accuracy to

204 ly, with increases in the incidence rate and thyroid cancer mortality rate for advanced-stage papilla

205 papillary thyroid cancer has been related to thyroid cancer mortality trends.

206 Familial medullary thyroid cancer (MTC) and its precursor, C cell hyperplas

207 Medullary thyroid cancer (MTC) can be caused by germline mutations

208 cluding small cell lung cancer and medullary thyroid cancer (MTC).

209 ncer (AJCC) TNM staging system for medullary thyroid cancer (MTC).

210 Cases with thyroid cancer (n = 104) were recruited from 1992 to 200

211 zed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and

212 gic type (64625 cases), and 2371 deaths from thyroid cancer occurred during 1994-2013.

213 internal radiation dosimetry, in humans with thyroid cancer, of (18)F-tetrafluoroborate ((18)F-TFB),

214 good prognosis; the 5-year survival rate for thyroid cancer overall is 98.1%.

215 advances are yielding critical insights into thyroid cancer pathogenesis, which are being leveraged f

216 an be used as a reliable tool for staging of thyroid cancer patients and individualized treatment pla

217 124)I PET/CT data on BMs from differentiated thyroid cancer patients were retrospectively analyzed to

218 Data from 211 thyroid cancer patients who received (124)I blood dosime

219 iric fixed RAI activity in the management of thyroid cancer patients with RAI-avid distant metastases

220 iric fixed RAI activity in the management of thyroid cancer patients with RAI-avid distant metastases

221 points were examined retrospectively for 65 thyroid cancer patients, referred to determine (131)I up

222 X were associated with decreased survival in thyroid cancer patients.

223 noticeably higher rate with sorafenib use in thyroid cancer patients.

224 Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC

225 at rapidly progress to poorly differentiated thyroid cancer (PDTC).

226 yroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC).

227 ansplantation (lung, colorectal, kidney, and thyroid cancers, plus melanoma).

228 Despite certain unique aspects of follicular thyroid cancer presentation and prognosis, no specific r

229 explain the clinically observed decrease in thyroid cancer prevalence in patients with co-existent P

230 tigated the relationship between the TME and thyroid cancer progression in a mouse model where thyroi

231 as pivotal features of the TME in promoting thyroid cancer progression, illuminating candidate thera

232 regulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX ta

233 ene in malignant melanoma (MM) and papillary thyroid cancer (PTC) and is causally involved in maligna

234 e highly associated with increased papillary thyroid cancer (PTC) risk with an odds ratio of approxim

235 Papillary thyroid cancer (PTC) was diagnosed in 97% of patients an

236 lti-generation CS-like family with papillary thyroid cancer (PTC), applying a combined linkage-based

237 ctor in the risk stratification of papillary thyroid cancer (PTC), but whether this is generally appl

238 o play a unique prognostic role in papillary thyroid cancer (PTC), with a distinct staging dichotomiz

239 promoter mutations can coexist in papillary thyroid cancer (PTC).

240 promoter mutations can coexist in papillary thyroid cancer (PTC).

241 rine model of Braf(V600E) -induced papillary thyroid cancer (PTC).

242 ) in non-carcinogenic thyroids and papillary thyroid cancer (PTC).

243 atients age 45 years or older with papillary thyroid cancer (PTC); patients younger than age 45 years

244 V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to poorly di

245 n is found in approximately 40% of papillary thyroid cancers (PTC).

246 Genome Atlas study (TCGA study) of papillary thyroid cancers (PTC).

247 ; P < .001; melanoma: R = 0.36; P = .01; and thyroid cancer: R = 0.30; P = .03).

248 ng been associated with the thyroid and with thyroid cancers, raising seminal questions about the rol

249 confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine and posi

250 progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had

251 ancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist t

252 ancers, non-Hodgkin lymphomas, and medullary thyroid cancers represent novel indications for the in v

253 s with radioiodine-refractory differentiated thyroid cancer (RR-DTC).

254 f human poorly differentiated and anaplastic thyroid cancers screened by next-generation sequencing u

255 eview the benefits and harms associated with thyroid cancer screening and treatment of early thyroid

256 s (n = 5894) directly addressed the harms of thyroid cancer screening, none of which suggested any se

257 ity studies directly examined the benefit of thyroid cancer screening.

258 tochondrial genomes in renal chromophobe and thyroid cancers show particularly strong signals of posi

259 sarcoma (SIR, 2.6; 95% CI, 1.5 to 4.4), and thyroid cancer (SIR, 1.9; 95% CI, 1.0 to 3.5).

260 Papillary thyroid cancer-specific mortality for cases with both mu

261 Results: Papillary thyroid cancer-specific mortality occurred in 4 of 629 p

262 Papillary thyroid cancer-specific mortality occurred in 4 of 629 p

263 This study aimed to assess the overall and thyroid cancer-specific survival in a large cohort of pa

264 , sex, primary malignancy, overall survival, thyroid cancer-specific survival, FNA, and histopatholog

265 correction of iodine deficiency might shift thyroid cancer subtypes toward less malignant forms.

266 sociated methylation differences between the thyroid cancer subtypes were linked to differential gene

267 e to distinguish between two uterine and two thyroid cancer subtypes.

268 long noncoding RNA (lncRNA) gene, papillary thyroid cancer susceptibility candidate 2 (PTCSC2).

269 (RAI) treatment in patients with metastatic thyroid cancer (TC) is still a matter of debate.

270 ostic significance of molecular signature in thyroid cancer (TC) is undefined but can potentially cha

271 he discovery of a locally advanced medullary thyroid cancer that is not amenable to surgery or of dis

272 d a gene expression signature from zebrafish thyroid cancer that is predictive of disease-free surviv

273 F and PTTG have a critical role in promoting thyroid cancer that is predictive of poorer patient outc

274 er study involving patients with progressive thyroid cancer that was refractory to iodine-131, we ran

275 l spheroid CSC lines derived from anaplastic thyroid cancer that were even more enriched with stem ce

276 The genomic landscape of thyroid cancers that are derived from follicular cells h

277 ter than small, given the relative rarity of thyroid cancer, the apparent lack of difference in outco

278 ed using the primary search terms molecular, thyroid cancer, thyroid nodule, and gene expression clas

279 ensively review the literature on follicular thyroid cancer to provide an evidence-based guide to the

280 the association of insurance expansion with thyroid cancer treatment using the 2006 Massachusetts he

281 Change in the thyroidectomy rate for thyroid cancer treatment was the primary outcome evaluat

282 he 2006 Massachusetts health care reform and thyroid cancer treatment, and participants were controll

283 SCs with a fibrotic fingerprint in papillary thyroid cancer tumors and the autocrine-paracrine conver

284 ients with surgically treated differentiated thyroid cancer undergoing their first radioiodine therap

285 We extended our findings to human thyroid cancer using TCGA data sets (n=322) and found st

286 at 8 +/- 2 months for the 752 patients with thyroid cancer, using the Short Form-36 and the EuroQoL-

287 y applied in the treatment of differentiated thyroid cancer was assessed using (124)I PET/CT.

288 Thyroid cancer was diagnosed in 5 original nodules (0.3%

289 The risk of thyroid cancer was higher for participants with a high b

290 ize increase during 5 years of follow-up and thyroid cancer was rare.

291 ith thyroid cancer from 1974-2013, papillary thyroid cancer was the most common histologic type (6462

292 One of 5 medullary thyroid cancers was positive with the agonist, whereas 5

293 cohort of patients with well-differentiated thyroid cancer (WDTC) treated or not with radioactive io

294 concentrations of PBDE were associated with thyroid cancer, we conducted a nested, case-control stud

295 scans of 5 subjects with recently diagnosed thyroid cancer were acquired before surgery for up to 4

296 diagnosed with localized >/= 1-cm papillary thyroid cancer who underwent thyroidectomy with one or m

297 reatment of patients with advanced medullary thyroid cancer with emphasis on current targeted therapi

298 Because of the rare possibility of an thyroid cancer with inclusion of mature fat, sonographic

299 Patients who undergo surgery for papillary thyroid cancer with only a limited lymph node examinatio

300 es (n = 291796), treatment of differentiated thyroid cancer with radioactive iodine is associated wit